--- schema_version: "secwatch.filing_event.v1" accession: "0000950170-23-051187" form_type: "8-K" ticker: null cik: "0001604477" company_name: "SQZ Biotechnologies Co" filed_at: "2023-10-02T23:59:59+00:00" generated_at: "2026-06-10T06:22:23.544377+00:00" event_type: "other_material" sentiment: "negative" materiality_score: 0.85 calibrated_materiality_score: 0.85 confidence: "high" source: SEC EDGAR --- # SQZ Biotech cuts ~80% of workforce, estimates $22M non-cash impairment ## Summary - Board approved ~80% workforce reduction on Sep 29, 2023 to cut costs while pursuing strategic alternatives. - Expected $1.5M in severance charges (mostly Q3 2023); ~$100K cash expenditure. - Non-cash impairment of ~$22M related to facility lease right-of-use asset and equipment. - Interim CEO, CAO, CMO, and GC to have reduced salaries and terminate Nov 15, 2023; may become consultants. - Company plans to continue treating currently enrolled patients in eAPC and AAC programs for HPV16+ tumors. ## SEC filing metadata - accession: 0000950170-23-051187 - form_type: 8-K - cik: 0001604477 - company_name: SQZ Biotechnologies Co - filed_at: 2023-10-02T23:59:59+00:00 - event_type: other_material - sentiment: negative - materiality_score: 0.85 - calibrated_materiality_score: 0.85 - confidence: high - sec_items: 2.05, 2.06, 5.02 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1604477/000095017023051187/0000950170-23-051187-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604477/000095017023051187/sqzb-20230929.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0000950170-23-051187 - JSON: https://secwatch.observer/filing/0000950170-23-051187.json - Plain text: https://secwatch.observer/filing/0000950170-23-051187.txt ## Key facts - Executive change Marshelle Smith Warren was terminated as Chief Medical Officer at SQZ Biotechnologies Co. - Action: terminated - Role: Chief Medical Officer source text: the Company and each of Howard Bernstein, Ph.D., Interim Chief Executive Officer of the Company, Richard Capasso, Chief Accounting Officer of the Company, Marshelle Smith Warren, M.D., Chief Medical Officer of the Company, and Lawrence Knopf, General Counsel of the Company (collectively, the “Executive Officers”) entered into a transition agreement amending the terms of the Executive Officer’s employment agreement with the Company. The transition agreements provide for an agreed employment termination date for the Executive Officers of November 15, 2023 evidence_url: https://www.sec.gov/Archives/edgar/data/1604477/000095017023051187/0000950170-23-051187-index.htm - Executive change Lawrence Knopf was terminated as General Counsel at SQZ Biotechnologies Co. - Action: terminated - Role: General Counsel source text: the Company and each of Howard Bernstein, Ph.D., Interim Chief Executive Officer of the Company, Richard Capasso, Chief Accounting Officer of the Company, Marshelle Smith Warren, M.D., Chief Medical Officer of the Company, and Lawrence Knopf, General Counsel of the Company (collectively, the “Executive Officers”) entered into a transition agreement amending the terms of the Executive Officer’s employment agreement with the Company. The transition agreements provide for an agreed employment termination date for the Executive Officers of November 15, 2023 evidence_url: https://www.sec.gov/Archives/edgar/data/1604477/000095017023051187/0000950170-23-051187-index.htm - Executive change Howard Bernstein was terminated as Interim Chief Executive Officer at SQZ Biotechnologies Co. - Action: terminated - Role: Interim Chief Executive Officer source text: the Company and each of Howard Bernstein, Ph.D., Interim Chief Executive Officer of the Company, Richard Capasso, Chief Accounting Officer of the Company, Marshelle Smith Warren, M.D., Chief Medical Officer of the Company, and Lawrence Knopf, General Counsel of the Company (collectively, the “Executive Officers”) entered into a transition agreement amending the terms of the Executive Officer’s employment agreement with the Company. The transition agreements provide for an agreed employment termination date for the Executive Officers of November 15, 2023 evidence_url: https://www.sec.gov/Archives/edgar/data/1604477/000095017023051187/0000950170-23-051187-index.htm - Executive change Richard Capasso was terminated as Chief Accounting Officer at SQZ Biotechnologies Co. - Action: terminated - Role: Chief Accounting Officer source text: the Company and each of Howard Bernstein, Ph.D., Interim Chief Executive Officer of the Company, Richard Capasso, Chief Accounting Officer of the Company, Marshelle Smith Warren, M.D., Chief Medical Officer of the Company, and Lawrence Knopf, General Counsel of the Company (collectively, the “Executive Officers”) entered into a transition agreement amending the terms of the Executive Officer’s employment agreement with the Company. The transition agreements provide for an agreed employment termination date for the Executive Officers of November 15, 2023 evidence_url: https://www.sec.gov/Archives/edgar/data/1604477/000095017023051187/0000950170-23-051187-index.htm - Restructurings & Charges SQZ Biotechnologies Co announced a impairment with charges of approximately $22 million affecting facility lease right of use asset and certain equipment. - Type: impairment - Charge: approximately $22 million - Affected area: facility lease right of use asset and certain equipment source text: Due to the Workforce Reduction and resulting reduced space requirements, the Company currently estimates that it will recognize a non-cash impairment charge of approximately $22 million related to its facility lease right of use asset and certain equipment. evidence_url: https://www.sec.gov/Archives/edgar/data/1604477/000095017023051187/0000950170-23-051187-index.htm - Restructurings & Charges SQZ Biotechnologies Co announced a restructuring with charges of approximately $1.5 million affecting workforce across the Company (approximately eighty percent). - Type: restructuring - Charge: approximately $1.5 million - Affected area: workforce across the Company - Headcount: approximately eighty percent source text: in its enhanced antigen presenting cell (eAPC) and activating antigen carriers (AAC) programs in HPV16+ tumors. The Company currently estimates that it will incur approximately $1.5 million in charges in connection with the Workforce Reduction, primarily consisting of employee-related benefits and related costs including continuation of group health insurance evidence_url: https://www.sec.gov/Archives/edgar/data/1604477/000095017023051187/0000950170-23-051187-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.